Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 10Etoposide 6Doxorubicin 6Cytarabine 6Prednisone 5Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4Methotrexate 4gamma-Globulins 3Rituximab 3Radiotherapy 3Filgrastim 3Ciprofloxacin 3pegaspargase 2nelarabine 2etoposide phosphate 2calaspargase pegol 2Triptorelin Pamoate 2Thioguanine 2Prednisolone 2Methylprednisolone 2Mercaptopurine 2Melphalan 2Magnetic Resonance Spectroscopy 2Immunoglobulins, Intravenous 2Dexamethasone 2Daunorubicin 2Cyclosporine 2Calcium Dobesilate 2Bortezomib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma × vedolizumab × Clear all
NCT06475820 2024-08-23

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Active not recruiting
150 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡